Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials (opens in a new tab)

news-medical.net · 2026-11-02

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1

The story

Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

news-medical.net · 2026-11-02

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 5Not checkedQureight says it has published a peer-reviewed Viewpoint in the European Respiratory Journal.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 5Not checkedThe paper argues that fibrosis extent should be considered the principal structural imaging biomarker in antifibrotic clinical trials and the leading imaging candidate for FDA biomarker qualification.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 5Not checkedThe article says FVC is the current registrational primary endpoint in antifibrotic trials, but it is a downstream measure of overall lung function and is influenced by more than fibrosis alone.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 5Not checkedQureight argues that quantitative HRCT measurement of fibrosis extent can complement FVC by giving a more biologically proximate view of whether therapy is slowing pulmonary fibrosis.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 5Not checkedThe company says that for fibrosis extent to become a surrogate endpoint in antifibrotic trials, more evidence is needed, including trial-level data linking treatment-driven changes in fibrosis accumulation to patient outcomes such as how patients feel, function, or survive.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 38 candidate papers

And 32 more candidates considered.